Skip to main content
SpringerLink
Log in
Book cover

Encyclopedia of Cancer pp 1–4Cite as

Renal Cancer Trends in Molecularly Targeted Therapies

  • Living reference work entry
  • First Online:

  • 32 Accesses

Definition

Today, the oncologist is armed with a multitude of active agents for the therapy of advanced renal cell carcinoma (RCC). This stands in sharp contrast to the landscape that existed just several years ago, at which time only interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) were available. Both of these agents yield limited clinical benefit in most cases, with IL-2 offering only a small chance of a durable response. An enhanced understanding of pathways related to RCC tumorigenesis has led to the development of clinically validated targeted therapies. At present, these agents can be broadly divided into two classes, inhibitors of vascular endothelial growth factor (VEGF)-mediated signaling and inhibitors of the mammalian target of rapamycin (mTOR). Through different mechanisms, both classes antagonize angiogenesis – notably, enhanced angiogenesis as a result of mutation in the von Hippel-Lindau tumor suppressor gene(VHL gene) and consequent accumulation of...

This is a preview of subscription content, log in via an institution.

References

  • Escudier B, Eisen T, Stadler WM et al (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  CAS  PubMed  Google Scholar 

  • Escudier B, Pluzanska A, Koralewski P et al (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111

    Article  Google Scholar 

  • Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289

    Article  CAS  Google Scholar 

  • Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    Article  CAS  PubMed  Google Scholar 

  • Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084–1096

    Article  CAS  PubMed  Google Scholar 

  • Klapper JA, Downey SG, Smith FO et al (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 113:293–301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xin H, Zhang C, Herrmann A et al (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69:2506–2513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, USA

    Robert A. Figlin

  2. Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Sumanta Kumar Pal

Authors
  1. Robert A. Figlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumanta Kumar Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A. Figlin .

Editor information

Editors and Affiliations

  1. Abt. Tumorgenetik, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    Manfred Schwab

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Figlin, R.A., Pal, S.K. (2014). Renal Cancer Trends in Molecularly Targeted Therapies. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6554-3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27841-9_6554-3

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-27841-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation